1 / 13

Welcome to Aktiv-Dry

Welcome to Aktiv-Dry. What We Do. Project management and systems integration Craft synergistic relationships License our technologies Technology transfer Build/Assemble Bubble Dryers and PuffHalers to clients’ specs. cGMP unit at SIIL in India

jamese
Download Presentation

Welcome to Aktiv-Dry

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Welcome to Aktiv-Dry

  2. What We Do • Project management and systems integration • Craft synergistic relationships • License our technologies • Technology transfer • Build/Assemble Bubble Dryers and PuffHalers to clients’ specs • cGMP unit at SIIL in India • Special unit for Sandia’s “energetic” compounds • Formulate clients’ compounds as dry powders • Alternative to lyophilization • Improved stability • Remove residual solvents • Engineer particle size for • Regional deposition by inhalation or other administration • Enhancing dissolution rates

  3. Intellectual Property • Five domestic patents • CAN-BD, Spray-freeze drying • Foreign patents • Europe, U.K., Germany, France, Switzerland, China, Australia • Japan application • Three domestic applications • PuffHaler, myo-Inositol formulations • One PCT application • Sublingual delivery, myo-Inositol stabilizer • Trademarks

  4. Company Background • Aktiv-Dry founded in 2002 • Privately held • Organized as a Colorado LLC • University of Colorado spinout • Exclusive license from CU to core technology, with right to sublicense • www. aktiv-dry.com

  5. Management • Bob Sievers – Co-founder, CEO • Prof. Chemistry & Biochemistry, CU Boulder. Former Regent. • Co-founder Sievers Instruments Ionics Sievers GE Analytical • Sculptor • Brian Quinn – Co-founder, Pres./COO • Engineer, Fluid Physicist, MBA • Co-founder, officer: Commercial Titan Inc., The Hintha Group, WyoChina Petroleum Inc., HydroMet Inc. • Sailboat Skipper, Mountaineer Ernst & Young Entrepreneur of the Year Finalists in 2006

  6. Core Technology The CAN-BD® Nebulizer - Heart of the Bubble Dryer® Near-critical or supercritical CO2 (80 to 100 atm) Drug solution or suspension Emulsion of product stream in liquid CO2 Flow restrictor tube ID = 75 µm 10 cm Restrictor tip CO2 flashes upon rapid 100X decompression to atmospheric pressure Plume Carbon dioxide Assisted Nebulization with a Bubble Dryer

  7. Bubble Dryer Capabilities Lab Scale Unit (1 g/hr) Development Scale Unit (4 g/hr)

  8. Spray Dryer Modified As A Bubble Dryer® • Modified Niro Production Minor by replacing the mechanical nebulizer with a CAN-BD nebulizer • Drying tower diameter 1.2 m • Cylindrical height 0.75 m • Conical height 0.9 m • 100 g/hr (or 10,000 doses of 10 mg each per hour) Production Scale Unit

  9. New Product - The PuffHaler® DPI • Designed • For needle-free delivery • For mass vaccination campaigns • To cost ≤ 10¢ per vaccination

  10. Representative Pharmaceutical Products Dried by CAN-BD

  11. Near-term Dry Powder Formulation Projects Pentavalent vaccine stabilization Hepatitis B stabilization and unit-dose packaging; myo-Inositol for inhibition of pulmonary carcinomas Broad spectrum vaccines Harmsen/Montana State University Aerosol delivery of HPV Garcea and Cape/University of Colorado Biodefense Bukeyrev/Galveston National Lab, others Early age measles vaccine delivery Griffin/Johns Hopkins, with manufacturers, others

  12. Conclusion We are eager to discuss interesting collaborative projects and other exciting business opportunities for which our technologies will enable new products Vaccines, other biologics, Anti-virals, antibiotics, anti-inflammatories Vectors Expressed genes, etc. Non-pharmaceutical

  13. CONTACTS • www.Aktiv-Dry.com • Telephone: (303) 350-3060; toll-free 866-690-7045 • Dr. Brian Quinn,, extension 101, • Dr. Pankaj Pathak, extension 112, • Dr. Bob Sievers, extension 106. • Mail: Aktiv-Dry LLC, 4900 Nautilus Ct. N, Suite 200, Boulder, CO 80301, USA

More Related